RxDoctor Payments Data

Ciro Ramirez, MD

Internal Medicine · Miami, FLNPI 1558547844

Payments from drug & device makers

$62,704in general payments, 2019–2025

Across 41 payments — averaging $1529.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$31K
  • Teva Pharmaceuticals USA, Inc.$29K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Merck$659

What the payments were for

  • Travel & lodging$1,75073%
  • Food & beverage$63727%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,704 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$83,065
Medicare patients
151
Services billed
1,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$72,121
OzempicSemaglutide50$55,543
JardianceEmpagliflozin55$35,194
EntrestoSacubitril/Valsartan29$26,358
JanuviaSitagliptin Phosphate37$22,195
XareltoRivaroxaban21$17,273
Tresiba Flextouch U-100Insulin Degludec15$13,104
JanumetSitagliptin Phos/Metformin Hcl19$9,366
FarxigaDapagliflozin Propanediol12$8,042
VascepaIcosapent Ethyl16$6,943
LinzessLinaclotide11$5,802
SymbicortBudesonide/Formoterol Fumarate17$3,390
Atorvastatin Calcium536$3,083
Losartan Potassium389$2,327
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$659$31,56056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →